Stocktoria
Dare Bioscience, Inc. DARE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-04-10
Dare Bioscience, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.0M | $9,784 | $2.8M | $10.0M | $0 |
| R&D expense | $5.5M | $14.3M | $21.5M | $30.0M | $30.6M |
| SG&A expense | $8.8M | $9.2M | — | — | — |
| Operating income | -$13.6M | -$23.5M | -$30.9M | -$31.4M | -$39.1M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$13.4M | -$4.1M | -$30.2M | -$30.9M | -$38.7M |
| EPS (diluted) | $-1.20 | $-0.48 | $-4.15 | $-0.37 | $-0.63 |
| Operating cash flow | -$9.9M | $5.5M | -$38.9M | -$18.1M | -$28.8M |
| Free cash flow | -$10.3M | $4.9M | -$39.5M | -$18.2M | -$28.8M |
| Cash & equivalents | $24.7M | $15.7M | $10.5M | $34.7M | $51.7M |
| Total assets | $32.5M | $22.1M | $21.3M | $43.8M | $55.8M |
| Total liabilities | $29.6M | $28.1M | $26.3M | $32.7M | $17.1M |
| Shareholders' equity | $2.8M | -$6.0M | -$5.0M | $11.1M | $38.8M |
Source: SEC EDGAR filings · CIK 0001401914 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.